Overall infection risk in rheumatoid arthritis during treatment with abatacept, rituximab and tocilizumab; an observational cohort study

Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden

(2019) Kathrine Lederballe Grøn et al.   ANNALS OF THE RHEUMATIC DISEASES

The Danish nationwide clinical register for patients with rheumatoid arthritis: DANBIO

(2016) Else Helene Ibfelt et al.   Clinical Epidemiology

Risk of infection with biologic antirheumatic therapies in patients with rheumatoid arthritis

(2015) Manjari Lahiri et al.   BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY

Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry

(2015) Ryoko Sakai et al.   ARTHRITIS RESEARCH & THERAPY

Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare

(2015) Huifeng Yun et al.   Arthritis & Rheumatology

The Danish National Patient Registry: a review of content, data quality, and research potential

(2015) Morten Schmidt et al.   Clinical Epidemiology

Infection risk in Rheumatoid Arthritis and Spondyloarthropathy patients under treatment with DMARDs, Corticosteroids and TNF-α antagonists

(2014) Valentina Germano et al.   Journal of Translational Medicine

Risk of Hospitalized Bacterial Infections Associated With Biologic Treatment Among US Veterans With Rheumatoid Arthritis

(2014) J. R. Curtis et al.   ARTHRITIS CARE & RESEARCH

Risk of infections in rheumatoid arthritis patients switching from anti-TNF agents to rituximab, abatacept, or another anti-TNF agent, a retrospective administrative claims analysis

(2013) Stephen S. Johnston et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment

(2012) J. Listing et al.   RHEUMATOLOGY

Existing data sources for clinical epidemiology: The Danish National Database of Reimbursed Prescriptions

(2012) Sigrun Alba Johannesdottir et al.   Clinical Epidemiology

The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents

(2011) J. R. Curtis et al.   ANNALS OF THE RHEUMATIC DISEASES

The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case-control study

(2011) W. G. Dixon et al.   ANNALS OF THE RHEUMATIC DISEASES

High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis

(2011) K. Au et al.   ANNALS OF THE RHEUMATIC DISEASES

Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?

(2011) A. Strangfeld et al.   ANNALS OF THE RHEUMATIC DISEASES

Healthy User and Related Biases in Observational Studies of Preventive Interventions: A Primer for Physicians

(2011) William H. Shrank et al.   JOURNAL OF GENERAL INTERNAL MEDICINE

The Danish National Patient Register

(2011) Elsebeth Lynge et al.   SCANDINAVIAN JOURNAL OF PUBLIC HEALTH

Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly

(2010) J. B. Galloway et al.   RHEUMATOLOGY

Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry

(2009) J D Greenberg et al.   ANNALS OF THE RHEUMATIC DISEASES